Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1Myeloid 1Gynecologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

venetoclax 190Cyclophosphamide 123Azacitidine 112Cytarabine 108fludarabine 91Specimen Handling 74Biopsy 53Daunorubicin 42Methotrexate 41Dexamethasone 38Rituximab 34blinatumomab 32Vincristine 32Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Whole-Body Irradiation 26Magnetic Resonance Spectroscopy 26obinutuzumab 25Idarubicin 25acalabrutinib 23Prednisone 23Mycophenolic Acid 23Melphalan 21Busulfan 21gilteritinib 19Mercaptopurine 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Fluid Therapy × Other hematologic neoplasm × Clear all
NCT06279572 2026-04-01

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Mayo Clinic

Recruiting
80 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06013423 2026-01-22

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Fred Hutchinson Cancer Center

Phase 2 Recruiting
54 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1 Recruiting
32 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡